The role of TMEM106B in ftld-TDP pathogenesis

Active Project Grant Awarded Last action

Award ID
F30AG085984
Recipient
Awarding agency
Obligated
$493,292

Award facts

Assistance listing
93.866 Aging Research
Completion date 80% complete
Place of performance
Jacksonville, FL 32224, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Alzheimer disease and related dementias (adrd) comprise a group of neurodegenerative diseases characterized by progressive decline of cognitive, behavioral, and/or motor function. These conditions place a significant burden on patients, families, and the healthcare system. Among the adrds is frontotemporal dementia (FTD), with approximately half of FTD cases characterized pathologically by frontotemporal lobar degeneration with TDP-43 pathology (ftld-TDP). Single nucleotide polymorphisms (snps) in TMEM106B are known to alter risk of ftld-TDP. TMEM106B is a protein localized to late endosomes and lysosomes and has been reported to play a role in endolysosomal trafficking and brain myelination. Only one TMEM106B SNP causes a coding change, altering the amino acid at position 185 from threonine to serine (T185S). The TT185 haplotype is associated with significantly increased risk of ftld-TDP relative to SS185. The SNP is also in high linkage disequilibrium with other TMEM106B snps, marking the coding change as a potential mechanism behind TMEM106B's modulation of disease risk. The coding SNP of TMEM106B has not been studied extensively, though the coding change has been reported to alter protein half-life and autophagic flux in the cell. Recently, four groups published the discovery of TMEM106B amyloid fibrils in sarkosyl-insoluble cortical lysates across a range of neurodegenerative diseases, including ftld-TDP. In preliminary studies, we have observed that accumulation of TMEM106B fibrils is positively associated with the TT185 haplotype. We speculate that the TMEM106B risk haplotype drives fibril formation and endolysosomal dysfunction, both of which contribute to neuron loss in disease. The studies outlined in this proposal will characterize the biological consequences of TMEM106B fibril formation in the diseased human brain and investigate TMEM106B haplotype-specific differences in endolysosomal function in a new cell model system. In aim 1, we will identify protein interactors of TMEM106B fibrils in postmortem ftld-TDP and non-diseased brains to test the hypothesis that TMEM106B fibrils exhibit disease-specific interactions that drive neuron loss. In aim 2, mechanistic studies will be performed in novel, isogenic ipsc-derived neuron models stably expressing TMEM106B coding variants to test the hypothesis that the TMEM106B risk haplotype impairs endolysosomal function. We will also assess mechanistic relationships between TMEM106B and top interactors identified in aim 1, and how they may vary with TMEM106B haplotype. We anticipate that this work will help identify novel protein targets to investigate or target for therapeutic development.

Transactions

Action Obligated Date
Amendment $576
Amendment $49,738
Amendment $49,738
Amendment $564
Amendment $564
Amendment $49,174
Amendment $49,174
Amendment $49,174
Amendment $49,174
Amendment $1,280
Amendment $1,280
Amendment $0
Amendment $0
Amendment $1,280
Amendment $47,894
Amendment $47,894
Amendment $47,894
Original award $47,894
Show all 18

Quick answers

Who received award F30AG085984?

F30AG085984 was awarded to Mayo Clinic Jacksonville (A Nonprofit Corporation) by National Institute on Aging (National Institutes of Health) on June 6, 2024.

How much is award F30AG085984 worth?

$493,292 has been obligated on F30AG085984.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login